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Abstract
Recent studies indicate relatively high international rates of adjunctive psychotropic medication, includ-
ing mood stabilizers, for patients with schizophrenia. Since such treatments are little studied in Asia, we
examined the frequency of mood-stabilizer use and its clinical correlates among hospitalized Asian
patients diagnosed with schizophrenia in 2001–2008. We evaluated usage rates of mood stabilizers with
antipsychotic drugs, and associated factors, for in-patients diagnosed with DSM-IV schizophrenia in 2001,
2004 and 2008 in nine Asian regions : China, Hong Kong, India, Korea, Japan, Malaysia, Taiwan, Thailand,
and Singapore. Overall, mood stabilizers were given to 20.4% (n=1377/6761) of hospitalized schizo-
phrenia patients, with increased usage over time. Mood-stabilizer use was signiﬁcantly and indepen-
dently associated in multivariate logistic modeling with : aggressive behaviour, disorganized speech, year
sampled (2008 vs. earlier), multiple hospitalizations, less negative symptoms, younger age, with regional
variation (Japan, Hong Kong, Singapore>Taiwan or China). Co-prescription of adjunctive mood stabil-
izers with antipsychotics for hospitalized Asian schizophrenia patients increased over the past decade,
and was associated with speciﬁc clinical characteristics. This practice parallels ﬁndings in other countries
and illustrates ongoing tension between evidence-based practice vs. individualized, empirical treatment of
psychotic disorders.
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Introduction
Recent pharmacoepidemiological studies evaluating
use of psychotropic drugs by patients with schizo-
phrenia have found substantial rates of co-treatment
with adjunctive mood stabilizers, at rates ranging
from 7% to 50% of patients in various countries, with
evidence of increasing use over time (Buchanan et al.
2002; Haro & Salvador-Carulla, 2006). In turn, use of
adjunctive mood stabilizers has been associated with
variance in the use of antipsychotic drugs, including
their number, doses, and duration (Centorrino et al.
2010; Galletly & Tsourtos, 1997 ; Mallinger & Lamberti,
2007). In some samples, use of mood stabilizers has
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been associated particularly with aggression or irrita-
bility (Kingsbury et al. 2001; Littrell et al. 2004),
persistent positive symptoms (Citrome, 2009), or as
supplementation of antipsychotics tolerated only at
moderate doses or with unsatisfactory responses
(Basan et al. 2004; Centorrino et al. 2010; Stahl, 2004).
Studies of psychotropic treatment practice in
schizophrenia are important to document changes
in the use of speciﬁc treatments over time, and to
investigate the basis of such trends. Associations of
adjunctive mood-stabilizer use with particular clinical
or demographic factors may support rational selection
of such treatments even without formal, prospective
and controlled trials, which remain rare (Buchanan
et al. 2010; Gorwood, 2006). In addition, such studies
may identify relevant adverse eﬀects or drug interac-
tions. Such information can guide consideration of
such treatments for other patients and encourage
speciﬁc hypotheses to be tested prospectively.
We were unable to identify any large-scale
pharmacoepidemiological studies of adjunctive
mood-stabilizer use for patients diagnosed with
schizophrenia in Asia, despite the huge burden of this
severe mental illness in this most populous part of
the world. Accordingly, we sought to : (1) elucidate the
prevalence of adjunctive mood-stabilizer use among
Asian in-patients diagnosed with schizophrenia in
2001, 2004, and 2008, and (2) identify clinical and other
selected correlates of this practice. Based on clinical
impressions and reports from other parts of the
world, we hypothesized that use of adjunctive mood
stabilizers (such as lithium, sodium valproate, carba-
mazepine, topiramate) would be relatively common,
might have increased in recent years, and be asso-
ciated with speciﬁc clinical or demographic features.
Methods
Study design and participants
The Research on East Asia Psychotropic Prescription
(REAP) study originated in 2001 as a pharmacoepi-
demiological project surveying trends regarding the
use of psychotropic drugs in schizophrenia in-patients
in six East Asian countries and regions (China, Hong
Kong, Japan, Korea, Singapore, Taiwan). Such studies
are rare, although there have been some comparisons
of treatments for hospitalized schizophrenia patients
between culturally dissimiler countries (Dollfus
et al. 1996; Kiivet et al. 1995). Studies of schizophrenia
patients in Asia are supported by widespread accept-
ance of DSM-IV (APA, 1994) and ICD-10 (WHO,
1992) as international standards for the diagnosis of
psychotic disorders. Methods of case ascertainment,
diagnosis, and treatment assessment used in this
study have been detailed previously (Sim et al.
2004a, b) and are summarized here.
In 2001, this project conducted a cross-sectional
study on a sample of 2399 consecutive adult (age
o18 yr) in-patients diagnosed with DSM-IV schizo-
phrenia (in PR China, SAR Hong Kong, Japan, RO
Korea, Singapore, Taiwan), based on a standardized
protocol. In 2004, we considered an independent rep-
lication sample of 2136 consecutive in-patients with
schizophrenia not included in the earlier study in 2001
in these six regions using the same procedures. In
2008, three other countries (Malaysia, India, Thailand)
joined this international project. Consensus meetings
were held at participating sites before the present
study to coordinate and standardize data acquisition
and management.
The study protocol and consent form were ap-
proved by the Institutional Research Boards of each
of the collaborating centres within the nine Asian
countries and territories, and all patient participants
provided written, informed consent for participation
and for anonymous and aggregate presentation of
study ﬁndings. Study patients fulﬁlled DSM-IV diag-
nostic criteria for schizophrenia (APA, 1994) and were
considered clinically stable by their primary psy-
chiatrists when recruited to participate. Patients with
clinically signiﬁcant medical illnesses or psychiatric
symptoms considered to be secondary to substance-
use disorders were excluded.
Data collected included basic sociodemographic
information, salient clinical features, and the names
and total daily doses of all psychotropic medicines
prescribed, including depot intramuscular injections
within 30 d of the index psychiatric hospitalization.
Daily doses of antipsychotic drugs, including depot
preparations, were converted to approximate chlor-
promazine equivalents (CPZ-eq) based on established
guidelines (Baldessarini & Tarazi, 2005 ; Centorrino
et al. 2010; Gardner et al. 2010; Kane et al. 1998).
Statistical analysis
Averages are reported as means¡standard deviations
(S.D.), and relative risks (among patients co-treated
with mood stabilizers or not) are reported as odds
ratios (OR) with their 95% conﬁdence intervals (CI),
based on the Statistical Package for Social Sciences
(SPSS Windows version 13.0 ; SPSS Inc., USA).
Normality of distributions of continuousmeasureswas
tested with the Kolmogorov–Smirnov one-sample test
before further analysis. Diﬀerences between groups
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(patients receiving vs. not receiving mood stabilizers)
were tested byANOVA (t test) for normally distributed
data, non-parametric Mann–Whitney U tests for non-
normally distributed continuous data. Contingency
tables (x2) were used for categorical variables. Analyses
of changes over years (2001–2008) excluded data from
Malaysia, India, and Thailand, which only joined the
project in 2008. Multivariate logistic regression ana-
lyses were performed to adjust for relevant covariates
and to determine the factors associated signiﬁcantly
and independently with adjunctive mood-stabilizer
treatment. Statistical signiﬁcance required two-tailed
p<0.01 to adjust for multiple comparisons.
Results
Demographic and clinical factors associated with
mood-stabilizer treatment
Salient demographic and clinical features of the study
populations sampled in 2001, 2004 and 2008 are shown
(Table 1). For the entire sample (N=6761), mean age
(with S.D. ; all o18 yr) was 43.5 (13.8) yr, including
3910 (57.8%) men and 2851 (42.2%) women. Of all
cases, 1310 (19.4%) represented ﬁrst-lifetime psychi-
atric hospitalizations. A total of 1377 (20.4%) patients
received an adjunctive mood stabilizer in addition to
one or more antipsychotic drugs.
For the six regions sampled in all three years (as
noted above), there was a signiﬁcant increase in the
prescription of mood stabilizers from 2001 to 2008
(x2=11.9, p=0.003). The inclusion of data from the
three countries added in 2008 made little diﬀerence in
this trend. However, for the six original countries,
there were larger increases in 2008 compared to either
2004 (23.7% vs. 19.5%; OR 1.28, 95% CI 1.10–1.49,
p=0.001) or 2001 (23.7% vs. 20.2%; OR 1.23, 95% CI
1.10–1.42, p=0.007). The most striking increases
were found with valproate, use of which more than
doubled between 2001 and 2008 (OR 2.43, 95% CI
2.00–2.94, p<0.001), and increased by 28% between
2004 and 2008 (OR 1.28, 95% CI 1.10–1.49, p=0.001)
in the six original Asian countries. In contrast, use
of lithium salts (2008 vs. 2001 : OR 0.74, 95% CI
0.57–0.95, p=0.02) and carbamazepine (OR 0.37, 95%
CI 0.28–0.50, p<0.001) declined by 26% and 63%,
respectively, in the same era. Overall, the most com-
monly prescribed adjunctive mood stabilizers were
valproate (11.1%)>lithium (5.6%)=carbamazepine
(5.6%)>lamotrigine (0.1%)=topiramate (0.1% of
cases). This ranking diﬀered somewhat between 2008
(valproate>lithium>carbamazepine>lamotrigine>
topiramate) and 2001 (carbamazepine>valproate>
lithium) (Table 2).
The gains in the use of valproate were associated
with a decline in the total daily dose of antipsychotic
drugs. The mean (S.D.) daily total CPZ-eq anti-
psychotic dose was approximately 580 (534) mg over-
all, and 633 (616) mg/d in 2001, 558 (505) mg/d in
2004, and 559 (458) mg/d in 2008.
Clinical correlates of adjunctive mood stabilizer
use in preliminary bivariate analyses
Patients who were prescribed adjunctive mood stabil-
izers in 2008 as well as in the entire 3-yr sample
were signiﬁcantly associated with relatively similar
demographic, clinical, and treatment factors (Tables 3
and 4). Overall, patients receiving mood stabilizers
were younger compared to those not given such
drugs, whereas sex distribution was similar in both
subgroups. Patients who received mood stabilizers
were more likely to have had multiple previous
psychiatric hospitalizations, and more likely to have
Table 1. Comparison of demographic and clinical features vs. years sampled
Measures 2001 (n=2399) 2004 (n=2136) 2008 (n=1906) Statisticsa p value
Current age, yr (S.D.) 43.6 (13.5) 43.1 (14.2) 45.5 (13.5) 16.5 <0.001
Proportion of men, n (%) 1340 (55.9) 1220 (57.2) 1167 (61.7) 15.4 0.001
First lifetime hospitalization, n (%) 387 (16.4) 443 (21.1) 343 (18.5) 15.8 <0.001
First-generation antipsychotics, n (%) 1627 (61.8) 1109 (51.9) 763 (40.3) 338 <0.001
Second-generation antipsychotics, n (%) 1092 (45.5) 1382 (64.7) 1460 (76.6) 449 <0.001
Depot antipsychotics, n (%) 384 (16.01) 205 (9.67) 192 (10.1) 54.3 <0.001
Dose CPZ-eq, mg/d (S.D.) 633 (616) 558 (505) 559 (458) 14.7 <0.001
Antipsychotic polytherapy, n (%) 1122 (46.8) 818 (38.3) 817 (42.9) 33.1 <0.001
Mood stabilizer use, n (%) 484 (20.2) 417 (19.5) 451 (23.7) 11.9 0.003
CPZ-eq, Chlorpromazine-equivalent total daily dose (mg).
a Statistics are x2 (categorical) or F value from ANOVA (continuous measures).
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positive psychotic symptoms (notably, delusions),
disorganized speech, or aggression, and less likely to
have negative symptoms. In addition, patients given
mood stabilizers were more likely to receive ﬁrst-
generation neuroleptics, more than one antipsychotic
agent, and a higher total daily dose of antipsychotics
than those not given a mood stabilizer. Not surpris-
ingly, they also were more likely to have higher
body-weight, and to experience adverse eﬀects such as
excessive sedation (Tables 3 and 4).
Multivariate modelling of factors associated with
adjunctive mood-stabilizer use
Based on multivariate logistic regression modelling,
with adjunctive mood-stabilizer use as the dependent
factor, associated factors, in descending order of OR,
were : (a) aggression (OR 1.89, 95% CI 1.58–2.27,
p<0.001) ; (b) disorganized speech (OR 1.43, 95% CI
1.25–1.65, p<0.001) ; (c) year sampled (2008 vs. 2001 : OR
1.37, 95% CI 1.16–1.61, p<0.001; or 2008 vs. 2004
(OR 1.41, 95% CI 1.20–1.67, p<0.001) ; (d) younger age
(OR 0.98, 95% CI 0.97–0.98, p<0.001) ; (e) less likelihood
of negative symptoms (OR 0.80, 95% CI 0.69–0.92,
p=0.002) ; and ( f ) less likelihood of ﬁrst-hospitalization
(OR 0.53, 95% CI 0.43–0.64, p<0.001) ; with (g) sig-
niﬁcant regional variation : less likely in China (OR 0.36,
95% CI 0.28–0.46, p<0.001) and more likely in Japan
(OR 1.73, 95% CI 1.40–2.10, p<0.001), Hong Kong (OR
1.51, 95% CI 1.12–2.03, p=0.006), or Singapore (OR
1.45, 95% CI 1.08–1.96, p=0.014) – all compared to
Taiwan (Table 5).
Table 3. Correlates of adjunctive mood-stabilizer use in all 6441 cases
Factors MS (n=1352) No MS (n=5089) Statisticsa p value
Current age, yr (S.D.) 42.8 (12.6) 44.3 (14.0) 3.41 (6420) 0.001
Current body-weight, kg (S.D.) 63.8 (13.8) 62.0 (12.7) 4.45 (6307) <0.001
CPZ-eq dose, mg/d (S.D.) 755 (680) 541 (483) 13.2 (6439) <0.001
Proportion of men, n (%) 789 (58.4) 2938 (57.7) 1.02 (0.90–1.15) 0.78
First-lifetime hospitalization, n (%) 148 (10.9) 1140 (22.4) 0.48 (0.40–0.58) <0.001
Delusions, n (%) 832 (61.5) 2908 (57.1) 1.20 (1.06–1.36) 0.004
Hallucinations, n (%) 692 (51.2) 2362 (46.4) 1.20 (1.07–1.36) 0.002
Disorganized speech, n (%) 446 (33.0) 1243 (24.4) 1.50 (1.30–1.70) <0.001
Negative symptoms, n (%) 626 (46.3) 2844 (55.9) 0.68 (0.60–0.81) <0.001
Aggression, n (%) 253 (18.7) 417 (8.20) 2.60 (2.20–3.10) <0.001
Weight gain, n (%) 110 (8.14) 369 (7.25) 0.88 (0.71–1.10) 0.27
Excess sedation, n (%) 75 (5.55) 172 (3.38) 1.70 (1.3–2.20) <0.001
Depot antipsychotics, n (%) 207 (15.31) 574 (11.3) 1.40 (1.20–1.69) <0.001
First-generation antipsychotics, n (%) 826 (61.1) 2673 (52.5) 1.42 (1.2–1.61) <0.001
Second-generation antipsychotics, n (%) 814 (60.2) 3120 (61.3) 1.05 (0.93–1.18) 0.47
Antipsychotic polytherapy, n (%) 709 (52.4) 2048 (40.2) 1.64 (1.45–1.85) <0.001
CPZ-eq, Chlorpromazine-equivalent ; MS, mood stabilizer.
a Statistics are based on: Student’s t test for continuous factors with t value (degree of freedom) ; or x2 test for categorical
factors with odds ratio (95% conﬁdence interval) for patients who did vs. did not receive an adjunctive mood stabilizer with
antipsychotics.







(n=1906) x2 p value
Valproate 183 (7.63) 232 (10.9) 318 (16.7) 87.2 <0.001
Lithium 163 (6.80) 117 (5.55) 97 (5.09) 6.42 0.04
Carbamazepine 205 (8.54) 107 (5.00) 64 (3.36) 56.0 <0.001
Topiramate 0 (0.00) 0 (0.00) 6 (0.31) 14.3 0.001
Lamotrigine 0 (0.00) 2 (0.09) 4 (0.21) 5.03 0.081
a Values are n (%).
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Other factors that were associated with mood-
stabilizer use in preliminary bivariate comparisons
were no longer associated in multivariate modelling.
These included: sex, presence of delusions or hal-
lucinations, use of ﬁrst-generation antipsychotics,
antipsychotic polytherapy, or use of a depot anti-
psychotics.
Discussion
There were several notable ﬁndings in this study. First,
there was a signiﬁcant trend of increased use of ad-
junctive mood stabilizers in the treatment of Asian
patients with schizophrenia over the past decade.
Second, use of mood stabilizers was associated with
multiple hospitalizations, certain psychopathology
(aggressive behaviour, more positive than negative
symptoms, disorganized speech), younger age, and
certain features of antipsychotic treatment (including
use of older neuroleptics, antipsychotic polytherapy,
higher total daily dose of antipsychotics, and more
adverse, treatment-associated eﬀects including higher
body-weight). Third, in the multivariate logistic re-
gression analyses, adjunctive mood-stabilizer use was
signiﬁcantly associated with younger age, multiple
hospitalizations, disorganized speech, aggression,
country, and more recent time-point. Some of these
clinical and treatment characteristics strongly suggest
unsatisfactory treatment responses that may well have
encouraged empirical addition of mood stabilizers.
In this study, we found increased use of mood
stabilizers over time particularly with valproate and
in association with some decrease in use of lithium
or carbamazepine. Similar trends have been noted by
investigators in other countries (Buchanan et al. 2002;
Table 4. Correlates of adjunctive mood stabilizer use in 2008 (N=2226)
Factors MS (n=476) No MS (n=1750) Statisticsa p value
Age, yr (S.D.) 43.1 (13.5) 44.1 (13.8) x1.44 (2206) 0.15
Body-weight, kg (S.D.) 65.4 (15.6) 62.7 (13.8) 3.54 (2109) <0.001
CPZ-eq dose, mg/day (S.D.) 664 (535) 512 (425) 6.53 (2224) <0.001
Proportion of men, n (%) 292 (61.3) 1058 (60.4) 1.02 (0.83–1.25) 0.92
First hospitalization, n (%) 72 (15.1) 419 (23.9) 0.46 (0.34–0.62) <0.001
Delusions, n (%) 342 (71.8) 1055 (60.3) 1.68 (1.35–2.10) <0.001
Hallucinations, n (%) 270 (56.7) 916 (52.3) 0.84 (0.68–1.03) 0.09
Disorganized speech, n (%) 125 (26.3) 385 (22.0) 1.26 (1.01–1.59) 0.05
Negative symptoms, n (%) 196 (41.2) 879 (50.2) 0.69 (0.56–0.85) <0.001
Aggression, n (%) 96 (20.2) 221 (12.6) 1.75 (1.34–2.78) <0.001
Weight gain, n (%) 49 (10.3) 168 (9.6) 0.93 (0.66–1.30) 0.66
Excess sedation, n (%) 42 (8.8) 109 (6.2) 1.46 (1.01–2.11) 0.046
Depot antipsychotics, n (%) 64 (13.4) 220 (12.6) 0.93 (0.69–1.25) 0.64
First-generation antipsychotics, n (%) 221 (46.4) 708 (40.5) 1.28 (1.04–1.56) 0.019
Second-generation antipsychotics, n (%) 368 (77.3) 1273 (72.7) 1.28 (1.01–1.62) 0.045
Antipsychotic polytherapy, n (%) 236 (49.6) 730 (41.7) 1.37 (1.1–1.68) 0.002
CPZ-eq, Chlorpromazine-equivalent dose (mg/d) ; MS, mood stabilizer.
a Statistics are based on : Student’s t test for continuous factors with t value (degree of freedom) ; or x2 test for categorical factors
with odds ratio (95% conﬁdence interval) for patients who did vs. did not receive an adjunctive mood stabilizer with anti-
psychotics.
Table 5. Factors associated with adjunctive mood-stabilizer
use (multivariate logistic regression modelling)
Factor OR 95% CI
Wald
test p value
Age, yr 0.98 0.9–0.98 35.3 <0.001
First admission 0.53 0.43–0.64 41.2 <0.001
Disorganized speech 1.43 1.25–1.65 25.8 <0.001
Negative symptoms 0.80 0.69–0.92 9.91 0.002
Aggression 1.89 1.58–2.27 46.8 <0.001
Year (vs. 2008)
2001 0.73 0.62–0.86 14.3 <0.001
2004 0.71 0.60–0.83 17.5 <0.001
Country (vs. Taiwan) 165 <0.001
China 0.36 0.28–0.46 64.2 <0.001
Japan 1.73 1.40–2.10 26.9 <0.001
Hong Kong 1.51 1.12–2.03 7.49 0.006
Singapore 1.45 1.08–1.96 6.09 0.014
OR, Odds ratio ; CI, conﬁdence interval.
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Centorrino et al. 2010; Citrome et al. 2000; Haro &
Salvador-Carulla, 2006). Buchanan et al. (2002) found
that up to 50% of their patients with schizophrenia
were prescribed an adjunctive medication including
mood stabilizers. More recently, Haro & Salvador-
Carulla (2006) examined in their naturalistic study
more than 10 000 patients with schizophrenia in 10
European countries and found that adjunctive mood
stabilizers were prescribed in 7–19% of patients. With
regard to longitudinal changes in mood-stabilizer use,
Citrome et al. (2000) reported an increase of adjunctive
mood stabilizer use from 26.2% to 43.4% after an
interval of 4 yr (1998 vs. 1994) in the treatment of
in-patients with schizophrenia, and speciﬁcally for
sodium valproate with a tripling of its use over the
same time period. Centorrino et al. (2010) similarly
observed an increase in adjunctive mood-stabilizer use
within hospitalized patients with schizophrenia over a
5-yr period from 2004 to 2009.
The basis of such striking growth in the use of
valproate in Asia is not readily explained, although its
popularity as a mood stabilizer in other countries may
reﬂect its relative ease of use, and the impact of ad-
vertising and clinical, word-of-mouth support, as well
as a simply empirical step in response to the typically
limited impact of treatment of patients with chronic
psychotic disorders (Baldessarini & Tarazi, 2005;
Basan et al. 2004; Citrome, 2009; Citrome et al. 2004;
Kreyenbuhl et al. 2007; Ventriglio et al. 2010). In ad-
dition, there may be speciﬁc indications for mood
stabilizers, including their eﬀectiveness in the control
of agitation, aggressive behaviours (Huband et al.
2010) or aﬀective features (Ventriglio et al. 2010). How-
ever, the pharmacodynamics of these mood stabilizers
such as sodium valproate do not provide ready ex-
planations for its recent popularity (Baldessarini &
Tarazi, 2005 ; Ichikawa et al. 2005; Wassef et al. 2003;
Winterer & Hermann, 2000). Moreover, there are very
few controlled studies of its use alone or as an adjunct
to antipsychotic drugs in the treatment of schizo-
phrenia patients (Buchanan et al. 2010; Schwarz et al.
2008). Most reported trials have been small, brief, and
do not support the eﬃcacy of valproate for psychotic
symptoms. In addition, evidence of the eﬀectiveness of
lithium (Collins et al. 1991; Terao et al. 1995; Wilson,
1993) or carbamazepine (Dose et al. 1987; Leucht et al.
2007), and other mood-stabilizing agents in the treat-
ment of psychotic disorder patients is also limited and
unconvincing.
The lack of speciﬁc, evidence-based treatment
recommendations regarding mood-stabilizer use for
schizophrenia patients leaves open the option of em-
pirical clinical trials of such treatments for individual
patients, particularly when standard antipsychotic
treatments are unsatisfactory or poorly tolerated
(Buchanan et al. 2010; Ventriglio et al. 2010). At the
same time, sound clinical practice calls for close con-
sideration of possible explanations of unsatisfactory
treatment responses, including poor adherence to
recommended treatment (Jo´nsdo´ttir et al. 2009), as
well as speciﬁc clinical monitoring for additional ad-
verse eﬀects or unfavourable drug–drug interactions
(Kelly et al. 2006).
There are several limitations to this study. The het-
erogeneity of the healthcare systems in the diﬀerent
sites and the focus on hospitalized patients, and only
those diagnosed with DSM-IV schizophrenia, limit
generalizability of the ﬁndings. Further, only three
years of the past decade were sampled, and three of
the nine countries or regions involved were sampled
only in 2008. It is also not always clear how the de-
cision was made to supplement antipsychotic treat-
ment with mood stabilizers for individual patients,
and clinically and individually decided treatment
preclude analysis of the clinical eﬀects of treatment
options with current data. In addition, assays of
serum concentration of drugs in order to evaluate
the adequacy of antipsychotic dosing or potential
pharmacokinetic interactions, particularly between
antipsychotic agents and some anticonvulsants
would have been of interest, but were not available
(Baldessarini & Tarazi, 2005).
In conclusion, this study found that prescription of
adjunctive mood stabilizers is a prevalent practice in
the management of schizophrenia in Asia that has in-
creased in recent years, especially regarding empirical
use of valproate. Adjunctive mood-stabilizer use
was associated with relative youth, and the presence
of aggression, positive symptoms, and disorganized
speech, as well as a history of multiple hospitalizations
and relatively aggressive antipsychotic treatment. In
addition, its association with use of ﬁrst-generation
neuroleptics, antipsychotic polytherapy, greater body-
weight and sedation all suggest that a mood stabilizer
was particularly likely to be added when aggressive
antipsychotic treatment was proving to be unsatisfac-
tory or poorly tolerated. Prudence calls for particularly
close clinical monitoring of patients treated with mul-
tiple psychotropic agents in whom the eﬃcacy and
safety of such applications remain poorly studied.
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